Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed FCF Margin for 6 consecutive years, with 30.17% as the latest value for Q3 2025.

  • For Q3 2025, FCF Margin rose 85436.0% year-over-year to 30.17%; the TTM value through Sep 2025 reached 48.16%, up 316524.0%, while the annual FY2024 figure was 216.65%, N/A changed from the prior year.
  • FCF Margin hit 30.17% in Q3 2025 for Cyclerion Therapeutics, up from 540.86% in the prior quarter.
  • Across five years, FCF Margin topped out at 19.93% in Q4 2024 and bottomed at 23314.52% in Q1 2021.
  • Average FCF Margin over 4 years is 3215.02%, with a median of 1195.06% recorded in 2025.
  • Year-over-year, FCF Margin tumbled -2029824bps in 2021 and then soared 2150931bps in 2022.
  • Cyclerion Therapeutics' FCF Margin stood at 1619.14% in 2021, then tumbled by -118bps to 3535.29% in 2022, then skyrocketed by 101bps to 19.93% in 2024, then plummeted by -251bps to 30.17% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 30.17%, 540.86%, and 1195.06% for Q3 2025, Q2 2025, and Q1 2025 respectively.